Literature DB >> 1880564

Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.

Y Ichiya1, Y Kuwabara, M Otsuka, T Tahara, T Yoshikai, T Fukumura, K Jingu, K Masuda.   

Abstract

In order to evaluate the usefulness of 18F-FDG PET in the assessment of therapeutic effects, FDG-PET studies were performed both before and after therapy in 26 patients with miscellaneous malignant tumors. The change in FDG uptake by therapy was compared with the change in tumor size and prognosis. All 26 lesions had a high FDG uptake before therapy. Five of seven lesions which had a relatively low FDG uptake before therapy showed no change or increase in tumor size by therapy. The decreased FDG uptake after therapy was more prominent in the partial response group than in the no change group. FDG uptake before therapy in the non-relapse group was higher than that in the relapse group. However, a decreased FDG uptake did not necessarily indicate a good prognosis. One patient with no change in tumor size and a decreased FDG uptake had no recurrence. This suggests that FDG-PET has a complementary role in the assessment of therapeutic effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1880564

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

1.  Detection of response to neoadjuvant therapy of esophageal squamous cell carcinoma by positron emission tomography (PET).

Authors:  G W Couper; K G M Park
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

2.  Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.

Authors:  H Minn; R Paul
Journal:  Eur J Nucl Med       Date:  1992

3.  Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.

Authors:  T Miyauchi; R L Wahl
Journal:  Eur J Nucl Med       Date:  1996-05

Review 4.  Axonal pathology in traumatic brain injury.

Authors:  Victoria E Johnson; William Stewart; Douglas H Smith
Journal:  Exp Neurol       Date:  2012-01-20       Impact factor: 5.330

5.  The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography.

Authors:  M Sasaki; Y Ichiya; Y Kuwabara; Y Akashi; T Yoshida; T Fukumura; S Murayama; T Ishida; K Sugio; K Masuda
Journal:  Eur J Nucl Med       Date:  1996-07

6.  FDG-PET in infectious lesions: The detection and assessment of lesion activity.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; Y Akashi; S Murayama; K Nakamura; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

7.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; J Omagari; Y Akashi; A Kawashima; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

8.  ¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes.

Authors:  Felipe A Calvo; Claudio V Sole; Dolores de la Mata; Luis Cabezón; Marina Gómez-Espí; Emilio Alvarez; Paz Madariaga; José L Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-23       Impact factor: 9.236

Review 9.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

10.  Combination treatment based on metabolic effects of dinaline.

Authors:  H Schaider; U Haberkorn; E Petru; M R Berger
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.